SpaceX (NASDAQ: SPCX) shares dropped 4% to $148.13 on Wednesday, as investors confronted a rare combination of supply, valuation, and insider-selling pressures simultaneously.
President and COO Gwynne Shotwell disclosed a plan to sell 342,170 shares with an aggregate value of nearly $52 million, adding to the market’s unease heading into a critical stretch.
The filing indicates that Shotwell acquired the shares through a cash exercise of stock options, and the transaction falls within a trading plan adopted in June.
That context means the planned sale doesn’t necessarily represent a fresh change in her outlook for the company, though the timing has clearly unsettled some investors.
SpaceX is also approaching a lockup expiration on September 24, when approximately 328 million shares are scheduled to become eligible for sale on the open market.
The expiration doesn’t require holders to sell, but the additional potential supply could weigh on the stock if early investors, employees, or other shareholders decide to monetize their positions.
AST SpaceMobile (NASDAQ: ASTS) fell 6% to $60.08 and Rocket Lab (NASDAQ: RKLB) declined 2% to $70.28, suggesting the selling pressure extended well beyond SpaceX alone.
The Procure Space ETF (NASDAQ: UFO) dropped 2% to $43.22, underperforming the Invesco QQQ Trust ETF (NASDAQ: QQQ), which declined a more modest 0.89% to $740.81.
That divergence reinforces the idea that space-related stocks are experiencing greater selling pressure than the broader technology market on the session.
SpaceX’s valuation has remained a live debate since the company’s June IPO, with the stock still holding above its $135 offering price despite Wednesday’s decline.
Barron’s reported that SpaceX had about 1.4 gigawatts of AI computing capacity at the end of the second quarter and plans to expand that capacity substantially in the quarters ahead.
Some of the company’s more ambitious AI-in-space plans remain dependent on Starship’s continued development, with a test flight currently scheduled for September 28.
The Starship test represents one of several near-term catalysts that could shift investor focus back toward operations rather than supply and valuation concerns.
Rocket Lab has its own potential catalysts, including its planned Neutron rocket and proposed acquisition of Iridium Communications, while AST SpaceMobile continues building its satellite-based cellular network.
For SpaceX, the critical question over the next several sessions is whether the market can absorb the new share supply without materially disrupting the stock’s current trading range.
Investors considering SpaceX or other space-related names may want to keep position sizes moderate given elevated valuations, share-supply uncertainty, and the substantial event-driven volatility that defines this sector.
